Synthesis and anti-breast cancer activity of tetrasubstituted pyrrole derivatives

Letters in Drug Design and Discovery

Volumn 2, Issue 7, 2005, Pages 529-532

  Padrón, José M ^a,b,c   Tejedor, David ^d   Santos Expóito, Alicia ^d   García Tellado, Fernando ^d   Villar, Jesús ^a   Martín, Víctor S ^c  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b Red Tematica de Investigacion Cooperativa en Cancer   (Spain)

^c UNIVERSIDAD DE LA LAGUNA   (Spain)

^d INSTITUTO DE PRODUCTOS NATURALES Y AGROBIOLOGÍA   (Spain)

Author keywords

Breast cancer; Diversity oriented synthesis; Privileged structure; Pyrroles; SU11248; Tyrosine kinase inhibitors

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; AMINE; ANTINEOPLASTIC AGENT; PHA 665752; PROTEIN TYROSINE KINASE INHIBITOR; PYRROLE DERIVATIVE; SEMAXANIB; SUNITINIB; UNCLASSIFIED DRUG;

ABSORPTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL; CELL STRAIN MCF 7; CONJUGATION; DRUG EFFECT; DRUG SYNTHESIS; HUMAN; IRRADIATION; PRIORITY JOURNAL;

EID: 28344458097     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018005774479122     Document Type: Article

References (24)

1. (a) Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J.Y.; Chu, J.Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T.C.; Tang, F.; Wei, J.; Tang, C. J. Med. Chem., 2003, 46, 1116;
2. (b) Sistla, A.; Sunga, A.; Phung, K.; Koparkar, A.; Shenoy, N. Drug Dev. Ind. Pharm., 2004, 30, 19.
3. (a) Mendel, D.B.; Laird, A.D.; Xin, X.; Louie, S.G.; Christensen, J.G.; Li, G.; Schreck, R.E.; Abrams, TJ.; Ngai T.J.; Lee, L.B.; Murray, L.J.; Carver, J.; Chan, E.; Moss, K.G. Haznedar, J.O.; Sukbuntherng, J.; Blake, R.A.; Sun, C.; Tang C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J.M. Clin. Cancer Res., 2003, 9, 327;
4. (b) O'Farrell, A.M.; Abrams, T.J.; Yuen, H.A.; Ngai, TJ.; Louie, S.G.; Yee, K.W.H.; Wong, L.M.; Hong, W.M.; Lee, L.B.; Town, A.; Smolich, B.D.; Manning, W.C.; Murray, L.J.; Heinrich, M.C.; Cherrington, J.M. Blood, 2003, 101, 3597;
5. (c) Abrams, T.; Lee, L.B.; Murray, L.J.; Pryer, N.K.; Cherrington, J.M. Mol. Cancer Ther., 2003, 2, 471.
6. Sternberg, C.N. Ann. Oncol, 2005, 16(Supp. 3), iii17.
7. (a) Hoffmann, H.; Lindel, T. Synthesis 2003, 1753;
8. (b) Fürstner, A. Angew. Chem., Int. Ed. 2003, 42, 3582;
9. (c) O'Hagan, D. Nat. Prod. Rep. 2000, 17, 435 and references therein;
10. (d) Le Quesne, P.W.; Dong, Y.; Blythe, T.A. In Alkaloids: Chemical and Biological Perspectives; Pelletier S.W., Ed.; Pergamon: Elmsford, New York, 1999; Vol. 13, pp. 238;
11. (e) Jones, R. A. In Pyrroles, Part II, The Synthesis, Reactivity and Physical Properties of Substituted Pyrroles; Wiley: New York, 1992.
12. (a) Huffman, J.W. Curr. Med. Chem. 1999, 6, 705;
13. (b) Cozzi, P.; Mongelli, N. Curr. Pharm. Des. 1998,4, 181;
14. (c) Colotta, V.; Cecchi, L.; Melani, F.; Filacchioni, G.; Martini, C.; Giannaccini, G.; Lucacchini, A. J. Med. Chem. 1990, 33, 2646.
15. (a) Guo T.; Hobbs D.W. Assay Drug Develop. Technol. 2003, 1, 579;
16. (b) Horton, D.A.; Bourne, G.T.; Smythe, M.L. Mol. Diver. 1999, 5, 289.
17. Tejedor, D.; González-Cruz, D.; García-Tellado, F.; Marrero-Tellado, J.J.; Rodríguez, M.L. J. Am. Chem. Soc. 2004, 126, 8390.
18. (a) Tejedor, D.; García-Tellado, F.; Marrero-Tellado, J.J.; de Armas, P. Chem.-Eur. J. 2003, 9, 3122;
19. (b) Tejedor, D.; López, G.V.; García-Tellado, F.; Marrero-Tellado, J.J.; de Armas, P.; Terrero, D. J. Org. Chem. 2003, 68, 3363;
20. (c) de Armas, P.; García-Tellado, F.; Marrero-Tellado, J.J.; Tejedor, D.; Maestro, M.A.; González-Platas, J. Org. Lett. 2001, 3, 1905.
21. Padrón, J.M.; Tejedor, D.; Santos-Expósito, A.; García-Tellado, F.; Martín, V.S.; Villar, J. Bioorg. Med. Chem. Lett., 2005, 15, 2487.
22. (a) Keepers, Y. P.; Pizao, P. E.; Peters, G. J.; Van Ark-Otte, J.; Winograd, B. Eur. J. Cancer 1991, 27, 897;
23. (b) Skehan, P.; Storeng, P.; Scudeiro, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. J. Natl. Cancer Inst 1990, 52, 1107.
24. Pure compounds were initially dissolved in DMSO at 400 times the desired final maximum test concentration, i.e. 100 μM. Control cells were exposed to an equivalent concentration of DMSO. Each agent was tested in duplicates at five different ten-fold dilutions. Drug incubation times were 48 h, after which cells were precipitated with 25 μL ice-cold 50% (w/v) trichloroacetic acid and fixed for 60 min at 4 °C. Then the SRB assay was performed. The optical density (OD) of each well was measured at 490 nm using Bio-Tek's Elx800 NB 96-well plate reader. The percentage growth was calculated at each of the drug concentration levels based on the difference in OD at the start and end of drug exposure. Values were corrected for background OD from wells only containing medium.